JANUSQ, LLC
Biotech · Private
HV-3, a peptide therapeutic that disrupts VCP-mtHtt interactions to reduce mitochondrial dysfunction and neuronal death in Huntington's Disease
- Grants
- $1.6M
- 4 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Pharmacokinetic Assessment of Peptide-Based Therapy HV-3 for the Treatment of Huntington's Disease | $240,938 | |
| Federal grant | Department of Health and Human Services · Phase I · Pharmacokinetic and pharmacodynamic assessment of peptide-based therapy DA1 for the treatment of Alzheimer's disease | $259,584 | |
| Federal grant | Department of Health and Human Services · Phase I · In vivo efficacy and in vitro toxicity assessment of peptide-based therapy HV-3 for the Treatment of Huntington's disease | $490,501 | |
| Federal grant | Department of Health and Human Services · Phase I · Pharmacokinetics and in vivo efficacy of DA1 macrocyclic peptides in a murine model of Alzheimer's disease | $576,664 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2882 | LABORECOM THERAPEUTICS INC. | — | — |
| 2883 | BIOCOGNON LLC | — | — |
| 2884 | MYOLOGICA, LLC | — | — |
| 2885 | JANUSQ, LLC | — | — |
| 2886 | FEMTOFLUIDICS INCORPORATED | — | — |
| 2887 | Origin Holdings Inc. | — | $137M |
| 2888 | RESVERLOGIX CORP. | — | $12M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.